Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreoni

Showing results (1121-1130 of 1,171) with videos related to

Pageof 118
Sort By:
The Journal of Antimicrobial Chemotherapy|January 25, 2020
HIV MDR is still a relevant issue despite its dramatic drop over the yearsD Armenia, D Di Carlo, P Flandre, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 10, 2020
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settingsDaniele Armenia, Yagai Bouba, Roberta Gagliardini, et al.
Antiviral Therapy|January 25, 2013
Impact of pre-therapy viral load on virological response to modern first-line HAARTMaria Mercedes Santoro, Daniele Armenia, Claudia Alteri, et al.
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
Antiviral Therapy|April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimenDaniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Plos One|December 24, 2019
Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter studyVeronica Bordoni, Bruno Brando, Pierluca Piselli, et al.
Frontiers in Pharmacology|July 5, 2021
Lactoferrin Against SARS-CoV-2: <i>In Vitro</i> and <i>In Silico</i> EvidencesElena Campione, Caterina Lanna, Terenzio Cosio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 25, 2016
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use ProgramAndreoni Massimo, Elisabetta Teti, Andrea Antinori, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 26, 2021
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-CVelia Chiara Di Maio, Silvia Barbaliscia, Elisabetta Teti, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14L Fabeni, C Alteri, D Di Carlo, et al.
Pageof 118

Showing results (1121-1130 of 1,171) with videos related to

Sort By:
Pageof 118
The Journal of Antimicrobial Chemotherapy|January 25, 2020
HIV MDR is still a relevant issue despite its dramatic drop over the yearsD Armenia, D Di Carlo, P Flandre, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 10, 2020
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settingsDaniele Armenia, Yagai Bouba, Roberta Gagliardini, et al.
Antiviral Therapy|January 25, 2013
Impact of pre-therapy viral load on virological response to modern first-line HAARTMaria Mercedes Santoro, Daniele Armenia, Claudia Alteri, et al.
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
Antiviral Therapy|April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimenDaniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Plos One|December 24, 2019
Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter studyVeronica Bordoni, Bruno Brando, Pierluca Piselli, et al.
Frontiers in Pharmacology|July 5, 2021
Lactoferrin Against SARS-CoV-2: <i>In Vitro</i> and <i>In Silico</i> EvidencesElena Campione, Caterina Lanna, Terenzio Cosio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 25, 2016
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use ProgramAndreoni Massimo, Elisabetta Teti, Andrea Antinori, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 26, 2021
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-CVelia Chiara Di Maio, Silvia Barbaliscia, Elisabetta Teti, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14L Fabeni, C Alteri, D Di Carlo, et al.
Pageof 118